Zoetis Inc. · ZTS · FY2024 Q3 · Calendar Q4 2024

Zoetis lifts 2024 outlook as companion-animal franchises drive growth

The supplied Q3 analysis describes strong operational growth across companion-animal franchises and a higher full-year revenue outlook. Sustaining that trajectory depends on product adoption and channel expansion overcoming competition, pricing pressure and cost headwinds.

Why did ZTS fall 3.7% after beating EPS estimates in FY2024 Q3?

Research this report with FN2. Free to start; review your question before sending.

Reported Before market openNYSEHealthcare $34.06B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $1.58 Consensus $1.46
EPS surprise +8.2% Reported versus consensus
Reported revenue $2.39B Consensus $2.29B
Revenue surprise +4.3% Reported versus consensus
Check the math in the surprise calculator >

Market reaction

prior-close to event-session close
Stock move -3.7% Event window
SPY move -0.2% Same window
Abnormal move -3.5% Stock minus SPY
Volume 2.2× Versus trailing sessions
Subsequent drift +1.0% Up to 20 sessions
ZTSSPY benchmark

Ask FN2 about ZTS FY2024 Q3

Choose a question to continue your research

Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.

Transcript intelligence

What changed

Compared with Q2, the Q3 analysis reports faster operational revenue growth and a further increase in 2024 revenue guidance. It also highlights Librela's continued U.S. penetration and Simparica Trio's scale, while identifying the Medicated Feed Additive divestiture as a Q4 revenue headwind.

Guidance delta

Management raised 2024 revenue guidance to $9.2–$9.3 billion, from the prior-quarter range of $9.1–$9.25 billion. The supplied analysis says the MFA divestiture is expected to reduce Q4 revenue but improve the longer-term margin profile.

Key takeaways

  • Revenue grew 14% operationally and adjusted net income rose 15% operationally, according to the supplied Q3 analysis.
  • Librela reached 85% U.S. penetration within 11 months, described in the analysis as the fastest launch in company history.
  • Simparica Trio became the number-one prescribed parasiticide, with 13 million dogs treated.
  • Full-year revenue guidance increased; the announced MFA divestiture is expected to weigh on Q4 revenue.

Management priorities

  • Expand Librela and Solensia globally, including into moderate osteoarthritis cases.
  • Grow Simparica Trio and Apoquel chewable through direct-to-consumer and retail channels.
  • Advance long-acting injectables, monoclonal antibodies and livestock genetics initiatives.

Follow ZTS with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
ZTS REVENUE earnings history estimate and actual scatter chart 10 reported fiscal quarters and 2 future estimate-only quarters. Q4 '23 estimate $2B Q4 '23 actual $2B, beat Q1 '24 estimate $2B Q1 '24 actual $2B, beat Q2 '24 estimate $2B Q2 '24 actual $2B, beat Q3 '24 estimate $2B Q3 '24 actual $2B, beat Q2 '25 estimate $2B Q2 '25 actual $2B, beat Q3 '25 estimate $2B Q3 '25 actual $2B, miss Q4 '25 estimate $2B Q4 '25 actual $2B, beat Q1 '26 estimate $2B Q1 '26 actual $2B, miss Q2 '26 estimate $3B Q2 '26 actual $2B, miss Q3 '26 estimate $2B Q3 '26 actual $2B, beat Q4 '26 estimate $2B Q1 '27 estimate $2B
Show less

Analyst Consensus ?

ConsensusHold32 ratings
Bullish1443.8%
Neutral1856.2%
Bearish00.0%

Analyst 52W Price Targets

$79.11Current
$74Low
$134.94Average
$254High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Morgan Stanley Overweight OverweightMaintainOct 29, 2026
UBS Neutral NeutralMaintainOct 27, 2026
Jefferies Hold BuyDowngradeOct 20, 2026
TD Cowen Buy BuyMaintainAug 25, 2026
Stifel Hold HoldMaintainAug 20, 2026
Show 27 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $79.11. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
Morgan StanleyAnalyst unavailable$82$77.86 +3.7%Oct 29, 2026
JefferiesKeith Devas$83$79.59 +4.9%Oct 20, 2026
Goldman SachsAnalyst unavailable$74$78.42 -6.5%Oct 16, 2026
Cantor FitzgeraldAnalyst unavailable$94$77.17 +18.8%Aug 25, 2026
Stifel NicolausJonathan Block$80$76.68 +1.1%Aug 20, 2026
See 32 more

Track every rating change on ZTS the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology.…

Historical context

All ZTS earnings

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
ASND Ascendis Pharma A/S FY2026 Q3 · Calendar Q4 2026 +38.7% +3.0% Ascendis Q3 growth broadens the story, while execution risks remain
ALC Alcon Inc. FY2026 Q3 · Calendar Q4 2026 +2.2% -2.3% Alcon holds FY outlook as new launches meet IOL competition

Latest beats and misses

Who reports next

Get the ZTS recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2024-11-10T18:38:36.707185+00:00
  3. Polygon adjusted daily market bars · 2026-11-16T13:10:47.825869+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-16T13:10:47.822569+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-11-16. For educational purposes only; not investment advice.